

# Multidrug-resistant Tuberculosis Management in Resou

Emerging Infectious Diseases

12, 1389-1397

DOI: [10.3201/eid1209.051618](https://doi.org/10.3201/eid1209.051618)

Citation Report

#	ARTICLE	IF	CITATIONS
1	HIV-1 Subtype and Reverse Transcriptase Genotype: Role for Geographical Location and Founder Effects. <i>PLoS Medicine</i> , 2006, 3, e540.	8.4	4
2	Cost-Effective Control of Drug-Resistant TB: Listening to Other Voices. <i>PLoS Medicine</i> , 2006, 3, e542.	8.4	0
3	Are Second-Line Drugs Necessary to Control Multidrug-Resistant Tuberculosis?. <i>Journal of Infectious Diseases</i> , 2006, 194, 1194-1196.	4.0	2
4	Building Capacity for Multidrug-Resistant Tuberculosis Treatment: Health Systems Strengthening in Lesotho. <i>Innovations</i> , 2007, 2, 87-106.	3.4	3
5	HIV Infection and Multidrug-Resistant Tuberculosis—The Perfect Storm. <i>Journal of Infectious Diseases</i> , 2007, 196, S86-S107.	4.0	390
6	Treatment of tuberculosis. <i>Expert Review of Respiratory Medicine</i> , 2007, 1, 85-97.	2.5	9
7	Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis: Implications for the HIV Epidemic and Antiretroviral Therapy Rollout in South Africa. <i>Journal of Infectious Diseases</i> , 2007, 196, S482-S490.	4.0	105
8	Multidrug-resistant and extensively drug-resistant <i>Mycobacterium tuberculosis</i> : epidemiology and control. <i>Expert Review of Anti-Infective Therapy</i> , 2007, 5, 857-871.	4.4	101
9	Management of multidrug-resistant tuberculosis: Update 2007. <i>Respirology</i> , 2008, 13, 21-46.	2.3	44
10	Tuberculosis, drug resistance, and HIV/AIDS: A triple threat. <i>Current Infectious Disease Reports</i> , 2007, 9, 252-61.	3.0	24
11	Multidrug resistant to extensively drug resistant tuberculosis: What is next?. <i>Journal of Biosciences</i> , 2008, 33, 605-616.	1.1	73
12	Multidrug-resistant tuberculosis. <i>BMC Infectious Diseases</i> , 2008, 8, 10.	2.9	109
13	Extensively drug-resistant tuberculosis in sub-Saharan Africa: an emerging public-health concern. <i>Transactions of the Royal Society of Tropical Medicine and Hygiene</i> , 2008, 102, 219-224.	1.8	20
14	Extensively drug-resistant tuberculosis: current challenges and threats. <i>FEMS Immunology and Medical Microbiology</i> , 2008, 53, 145-150.	2.7	106
15	Drug-resistant TB and HIV in resource-limited settings: what TB/HIV programmes can learn from each other. <i>Tropical Medicine and International Health</i> , 2008, 13, 1204-1207.	2.3	6
16	Developing new drugs for the treatment of drug-resistant tuberculosis: a regulatory perspective. <i>Tuberculosis</i> , 2008, 88, S93-S100.	1.9	33
17	Extensively drug-resistant tuberculosis: new strains, new challenges. <i>Expert Review of Anti-Infective Therapy</i> , 2008, 6, 713-724.	4.4	37
18	Extensively Drug-resistant Tuberculosis. <i>American Journal of Medicine</i> , 2008, 121, 835-844.	1.5	29

#	ARTICLE	IF	CITATIONS
19	XDR tuberculosis can be cured with aggressive treatment. <i>Lancet, The</i> , 2008, 372, 1363-1365.	13.7	8
20	Les résistances: définition opérationnelle et épidémiologique dans le monde. <i>Revue Des Maladies Respiratoires</i> , 2008, 25, 97-99.	1.7	0
21	Extensively Drug-Resistant Tuberculosis in the United States, 1993-2007. <i>JAMA - Journal of the American Medical Association</i> , 2008, 300, 2153.	7.4	104
22	Treatment Outcomes and Long-term Survival in Patients with Extensively Drug-resistant Tuberculosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2008, 178, 1075-1082.	5.6	157
23	Epidemiology and Treatment of Multidrug Resistant Tuberculosis. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2008, 29, 499-524.	2.1	37
24	Slow Elimination of Multidrug-Resistant Tuberculosis. <i>Science Translational Medicine</i> , 2009, 1, 3ra8.	12.4	17
25	Adjunctive resectional lung surgery for extensively drug-resistant tuberculosis. <i>European Respiratory Journal</i> , 2009, 34, 180-183.	6.7	38
26	Extensively drug-resistant tuberculosis in the UK: 1995 to 2007. <i>Thorax</i> , 2009, 64, 512-515.	5.6	22
27	Factors associated with death among HIV-uninfected TB patients in Thailand, 2004-2006. <i>Tropical Medicine and International Health</i> , 2009, 14, 1338-1346.	2.3	9
28	Doomsday postponed? Preventing and reversing epidemics of drug-resistant tuberculosis. <i>Nature Reviews Microbiology</i> , 2009, 7, 81-87.	28.6	154
29	Recent advances in the diagnosis and treatment of multidrug-resistant tuberculosis. <i>Respiratory Medicine</i> , 2009, 103, 1777-1790.	2.9	93
30	Treatment Outcomes of Multidrug-Resistant Tuberculosis: A Systematic Review and Meta-Analysis. <i>PLoS ONE</i> , 2009, 4, e6914.	2.5	346
31	Is standardized treatment appropriate for non-XDR multiple drug resistant tuberculosis cases? A clinical descriptive study. <i>Scandinavian Journal of Infectious Diseases</i> , 2009, 41, 10-13.	1.5	7
32	Pulmonary resection combined with isoniazid- and rifampin-based drug therapy for patients with multidrug-resistant and extensively drug-resistant tuberculosis. <i>International Journal of Infectious Diseases</i> , 2009, 13, 170-175.	3.3	37
33	First-line anti-tuberculosis drug resistance patterns and trends at the national TB referral center in Iran—eight years of surveillance. <i>International Journal of Infectious Diseases</i> , 2009, 13, e236-e240.	3.3	69
34	Treatment outcomes among patients with multidrug-resistant tuberculosis: systematic review and meta-analysis. <i>Lancet Infectious Diseases, The</i> , 2009, 9, 153-161.	9.1	486
35	Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis in the West. Europe and United States: Epidemiology, Surveillance, and Control. <i>Clinics in Chest Medicine</i> , 2009, 30, 637-665.	2.1	64
37	Emerging epidemic of drug-resistant tuberculosis in Europe, Russia, China, South America and Asia: current status and global perspectives. <i>Current Opinion in Pulmonary Medicine</i> , 2010, 16, 1.	2.6	18

#	ARTICLE	IF	CITATIONS
38	Recent advances in the diagnosis and treatment of multidrug-resistant tuberculosis. <i>Respiratory Medicine CME</i> , 2010, 3, 51-61.	0.1	9
39	Validation of the GenoType® MTBDRplus assay for detection of MDR-TB in a public health laboratory in Thailand. <i>BMC Infectious Diseases</i> , 2010, 10, 123.	2.9	56
40	Drug-resistant tuberculosis: Past, present, future. <i>Respirology</i> , 2010, 15, 413-432.	2.3	110
41	Multi-drug resistant tuberculosis burden and risk factors: An update. <i>Kathmandu University Medical Journal</i> , 2010, 8, 116-125.	0.2	27
42	Treatment Outcomes among Patients with Extensively Drug-Resistant Tuberculosis: Systematic Review and Meta-Analysis. <i>Clinical Infectious Diseases</i> , 2010, 51, 6-14.	5.8	235
43	<i>Mycobacterium tuberculosis</i> Phosphoribosylpyrophosphate Synthetase: Biochemical Features of a Crucial Enzyme for Mycobacterial Cell Wall Biosynthesis. <i>PLoS ONE</i> , 2010, 5, e15494.	2.5	19
44	Short, Highly Effective, and Inexpensive Standardized Treatment of Multidrug-resistant Tuberculosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2010, 182, 684-692.	5.6	596
45	Extensively Drug-Resistant Tuberculosis: A Sign of the Times and an Impetus for Antimicrobial Discovery. <i>Pharmaceuticals</i> , 2010, 3, 2268-2290.	3.8	47
46	Extensively Drug-Resistant Tuberculosis: "There must be some kind of way out of here". <i>Clinical Infectious Diseases</i> , 2010, 50, S195-S200.	5.8	69
47	The use of E-test for the drug susceptibility testing of <i>Mycobacterium tuberculosis</i> "A solution or an illusion?". <i>Indian Journal of Medical Microbiology</i> , 2010, 28, 30-33.	0.8	3
48	Multidrug-resistant tuberculosis: standardized or individualized treatment? The question has already been answered. <i>Expert Review of Respiratory Medicine</i> , 2010, 4, 143-146.	2.5	8
50	Multidrug-resistant and extensively drug-resistant tuberculosis: a threat to global control of tuberculosis. <i>Lancet</i> , The, 2010, 375, 1830-1843.	13.7	866
51	Expansion of cancer care and control in countries of low and middle income: a call to action. <i>Lancet</i> , The, 2010, 376, 1186-1193.	13.7	615
52	Drugs used in tuberculosis and leprosy. <i>Side Effects of Drugs Annual</i> , 2011, 33, 623-646.	0.6	0
53	Changes in the epidemiology of tuberculosis: the influence of international migration flows. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2011, 29, 654-659.	0.5	27
54	Outcomes of Multi-Drug Resistant Tuberculosis (MDR-TB) among a Cohort of South African Patients with High HIV Prevalence. <i>PLoS ONE</i> , 2011, 6, e20436.	2.5	89
55	Treatment of Tuberculosis in a Region with High Drug Resistance: Outcomes, Drug Resistance Amplification and Re-Infection. <i>PLoS ONE</i> , 2011, 6, e23081.	2.5	26
56	Recurrence after successful treatment among patients with multidrug-resistant tuberculosis. <i>International Journal of Tuberculosis and Lung Disease</i> , 2011, 15, 1331-1333.	1.2	13

#	ARTICLE	IF	CITATIONS
57	Health care provider obligations in caring for patients with tuberculosis. <i>International Journal of Tuberculosis and Lung Disease</i> , 2011, 15, 14-18.	1.2	0
58	Disease appearance and evolution against a background of climate change and reduced resources. <i>Philosophical Transactions Series A, Mathematical, Physical, and Engineering Sciences</i> , 2011, 369, 1719-1729.	3.4	25
59	Multidrug resistant tuberculous meningitis in the United States, 1993–2005. <i>Journal of Infection</i> , 2011, 63, 240-242.	3.3	15
60	Chapter 9. Current Approaches to Tuberculosis Drug Discovery and Development. <i>RSC Drug Discovery Series</i> , 2011, , 228-261.	0.3	0
61	Cost-effectiveness of novel vaccines for tuberculosis control: a decision analysis study. <i>BMC Public Health</i> , 2011, 11, 55.	2.9	22
62	Tuberculosis Drug Development. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2011, 184, 1107-1113.	5.6	13
63	Treatment of tuberculosis: update 2010. <i>European Respiratory Journal</i> , 2011, 37, 441-462.	6.7	92
64	Alternative Methods of Diagnosing Drug Resistance—What Can They Do for Me?. <i>Journal of Infectious Diseases</i> , 2011, 204, S1110-S1119.	4.0	22
65	Performance Assessment of the GenoType MTBDR <i>sl</i> Test and DNA Sequencing for Detection of Second-Line and Ethambutol Drug Resistance among Patients Infected with Multidrug-Resistant <i>Mycobacterium tuberculosis</i> . <i>Journal of Clinical Microbiology</i> , 2011, 49, 2502-2508.	3.9	96
66	Pulmonary resection for patients with multidrug-resistant tuberculosis: systematic review and meta-analysis. <i>Journal of Antimicrobial Chemotherapy</i> , 2011, 66, 1687-1695.	3.0	43
67	Rapid Diagnosis of Tuberculosis with the Xpert MTB/RIF Assay in High Burden Countries: A Cost-Effectiveness Analysis. <i>PLoS Medicine</i> , 2011, 8, e1001120.	8.4	264
68	Research on Implementation of Interventions in Tuberculosis Control in Low- and Middle-Income Countries: A Systematic Review. <i>PLoS Medicine</i> , 2012, 9, e1001358.	8.4	35
69	Novel Compounds and Drugs and Recent Patents in Treating Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis. <i>Recent Patents on Anti-infective Drug Discovery</i> , 2012, 7, 141-156.	0.8	7
70	Outcomes and follow-up of patients treated for multidrug-resistant tuberculosis in Orel, Russia, 2002–2005. <i>International Journal of Tuberculosis and Lung Disease</i> , 2012, 16, 1069-1074.	1.2	20
71	Management of children exposed to multidrug-resistant <i>Mycobacterium tuberculosis</i> . <i>Lancet Infectious Diseases</i> , The, 2012, 12, 469-479.	9.1	48
72	Rapid molecular detection of tuberculosis and rifampicin drug resistance: retrospective analysis of a national UK molecular service over the last decade. <i>Thorax</i> , 2012, 67, 361-367.	5.6	21
73	Relatively low primary drug resistant tuberculosis in southwestern Ethiopia. <i>BMC Research Notes</i> , 2012, 5, 225.	1.4	42
74	Predictors of poor outcomes among patients treated for multidrug-resistant tuberculosis at DOTS-plus projects. <i>Tuberculosis</i> , 2012, 92, 397-403.	1.9	123

#	ARTICLE	IF	CITATIONS
75	Cost and cost-effectiveness of multidrug-resistant tuberculosis treatment in Estonia and Russia. <i>European Respiratory Journal</i> , 2012, 40, 133-142.	6.7	42
76	Susceptibility testing to second-line drugs and ethambutol by Genotype MTBDRsl and Bactec MGIT 960 comparing with agar proportion method. <i>Tuberculosis</i> , 2012, 92, 417-421.	1.9	11
77	Health Related Quality of Life among Patients with Tuberculosis and HIV in Thailand. <i>PLoS ONE</i> , 2012, 7, e29775.	2.5	43
78	<i>Mycobacterium tuberculosis</i> mutants with multidrug resistance: History of origin, genetic and molecular mechanisms of resistance, and emerging challenges. <i>Russian Journal of Genetics</i> , 2012, 48, 1-14.	0.6	17
80	Multidrug-Resistant Tuberculosis: A Global Challenge. , 2013, , 89-119.		0
81	Ion-Pair Chromatography for Simultaneous Analysis of Ethionamide and Pyrazinamide from Their Porous Microparticles. <i>AAPS PharmSciTech</i> , 2013, 14, 1313-1320.	3.3	11
82	Decentralisation of multidrug-resistant-tuberculosis care and management. <i>Lancet Infectious Diseases</i> , The, 2013, 13, 644-646.	9.1	12
83	Drug-resistant tuberculosis: time for visionary political leadership. <i>Lancet Infectious Diseases</i> , The, 2013, 13, 529-539.	9.1	243
84	Tuberculosis treatment outcome monitoring in European Union countries: systematic review. <i>European Respiratory Journal</i> , 2013, 41, 635-643.	6.7	28
85	Multidrug-resistant tuberculosis. <i>Brazilian Journal of Infectious Diseases</i> , 2013, 17, 239-246.	0.6	16
86	Interrogating scarcity: how to think about 'resource-scarce settings'. <i>Health Policy and Planning</i> , 2013, 28, 400-409.	2.7	60
87	A Systematic Review of the Effectiveness of Hospital- and Ambulatory-Based Management of Multidrug-Resistant Tuberculosis. <i>American Journal of Tropical Medicine and Hygiene</i> , 2013, 89, 271-280.	1.4	63
88	Successful management of multidrug-resistant tuberculosis under programme conditions in the Dominican Republic. <i>International Journal of Tuberculosis and Lung Disease</i> , 2013, 17, 520-525.	1.2	39
89	Effect of Mycobacterial Drug Resistance Patterns on Patients's™ Survival: A Cohort Study in Thailand. <i>Global Journal of Health Science</i> , 2013, 5, 60-72.	0.2	6
90	Clinical Management of Drug-Resistant Tuberculosis in Resource Constrained Settings. <i>Clinical Medicine Insights Therapeutics</i> , 2013, 5, CMT.S6560.	0.4	0
91	Alcohol, Hospital Discharge, and Socioeconomic Risk Factors for Default from Multidrug Resistant Tuberculosis Treatment in Rural South Africa: A Retrospective Cohort Study. <i>PLoS ONE</i> , 2013, 8, e83480.	2.5	45
92	Drug-Resistant Tuberculosis – Diagnosis, Treatment, Management and Control: The Experience in Thailand. , 2013, , .		1
93	Management of Drug-Resistant TB. , 0, , .		1

#	ARTICLE	IF	CITATIONS
94	Potential Cost-Effectiveness of a New Infant Tuberculosis Vaccine in South Africa - Implications for Clinical Trials: A Decision Analysis. PLoS ONE, 2014, 9, e83526.	2.5	10
95	Association between Health Systems Performance and Treatment Outcomes in Patients Co-Infected with MDR-TB and HIV in KwaZulu-Natal, South Africa: Implications for TB Programmes. PLoS ONE, 2014, 9, e94016.	2.5	27
96	Use of Drug-Susceptibility Testing for Management of Drug-Resistant Tuberculosis, Thailand, 2004-2008. Emerging Infectious Diseases, 2014, 20, 408-416.	4.3	9
97	Drugs Used in Tuberculosis and Leprosy. Side Effects of Drugs Annual, 2014, , 445-456.	0.6	1
98	Treatment outcome of standardized regimen in patients with multidrug resistant tuberculosis. Journal of Pharmacology and Pharmacotherapeutics, 2014, 5, 145-149.	0.4	36
99	High cure rate with standardised short-course multidrug-resistant tuberculosis treatment in Niger: no relapses. International Journal of Tuberculosis and Lung Disease, 2014, 18, 1188-1194.	1.2	212
100	Prevalence of drug resistance in clinical isolates of tuberculosis from GCC: a literature review from January 2002 to March 2013. Journal of Infection in Developing Countries, 2014, 8, 1137-1147.	1.2	11
101	On the spread and control of MDR-TB epidemics: An examination of trends in anti-tuberculosis drug resistance surveillance data. Drug Resistance Updates, 2014, 17, 105-123.	14.4	33
102	"Home is where the patient is": a qualitative analysis of a patient-centred model of care for multi-drug resistant tuberculosis. BMC Health Services Research, 2014, 14, 81.	2.2	43
103	Comparing cost-effectiveness of standardised tuberculosis treatments given varying drug resistance. European Respiratory Journal, 2014, 43, 566-581.	6.7	17
104	Fifteen-year trend in treatment outcomes among patients with pulmonary smear-positive tuberculosis and its determinants in Arsi Zone, Central Ethiopia. Global Health Action, 2014, 7, 25382.	1.9	40
105	Experiences in anti-tuberculosis treatment in patients with multiple previous treatments and its impact on drug resistant tuberculosis epidemics. Global Health Action, 2014, 7, 24593.	1.9	6
106	Draft Genome Sequence of Multidrug-Resistant Mycobacterium tuberculosis Strain CWCFVRF MDRTB 670, Isolated from the Sputum of a Patient from Chennai, India, with Clinically Suspected Tuberculosis. Genome Announcements, 2014, 2, .	0.8	4
107	Characteristics and treatment outcomes of patients with multi-drug resistant tuberculosis at a tertiary care hospital in Peshawar, Pakistan. Journal of King Abdulaziz University, Islamic Economics, 2015, 36, 1463-1471.	1.1	22
108	Do HIV infection and antiretroviral therapy influence multidrug-resistant tuberculosis treatment outcomes?. African Journal of Pharmacy and Pharmacology, 2015, 9, 875-880.	0.3	6
109	Evaluation of macrolides for possible use against multidrug-resistant Mycobacterium tuberculosis. European Respiratory Journal, 2015, 46, 444-455.	6.7	20
110	Sputum culture conversion as a prognostic marker for end-of-treatment outcome in patients with multidrug-resistant tuberculosis: a secondary analysis of data from two observational cohort studies. Lancet Respiratory Medicine, the, 2015, 3, 201-209.	10.7	116
111	Management and treatment outcomes of MDR-TB: results from a setting with high rates of drug resistance. International Journal of Tuberculosis and Lung Disease, 2015, 19, 1109-1114.	1.2	56

#	ARTICLE	IF	CITATIONS
115	Epidemiological Trends of Drug-Resistant Tuberculosis in China From 2007 to 2014. <i>Medicine (United States)</i> , 2016, 95, 107-114.	1.6	27
116	Cost and cost-effectiveness of tuberculosis treatment shortening: a model-based analysis. <i>BMC Infectious Diseases</i> , 2016, 16, 726.	2.9	28
117	Proteomic analysis of sensitive and multi drug resistant <i>Mycobacterium tuberculosis</i> strains. <i>Microbiology</i> , 2016, 85, 350-358.	1.2	4
118	A Mutation in the 16S rRNA Decoding Region Attenuates the Virulence of <i>Mycobacterium tuberculosis</i> . <i>Infection and Immunity</i> , 2016, 84, 2264-2273.	2.2	9
119	Treatment outcomes for multidrug-resistant tuberculosis under DOTS-Plus: a systematic review and meta-analysis of published studies. <i>Infectious Diseases of Poverty</i> , 2017, 6, 7.	3.7	67
120	Design, synthesis and evaluation of indole-2-carboxamides with pan anti-mycobacterial activity. <i>Bioorganic and Medicinal Chemistry</i> , 2017, 25, 3746-3755.	3.0	56
121	Management of Tuberculosis in Special Populations. , 2017, , 141-190.		1
122	The experience of scaling up a decentralized, ambulatory model of care for management of multidrug-resistant tuberculosis in two regions of Ethiopia. <i>Journal of Clinical Tuberculosis and Other Mycobacterial Diseases</i> , 2017, 7, 28-33.	1.3	8
123	Handbook of Tuberculosis. , 2017, , .		3
124	Trends in drug-resistant tuberculosis after the implementation of the DOTS strategy in Shenzhen, China, 2000â€“2013. <i>International Journal of Tuberculosis and Lung Disease</i> , 2017, 21, 759-765.	1.2	7
125	Antituberculosis Agents. , 2017, , 1264-1276.e2.		1
126	Multidrug resistant tuberculosis in prisons located in former Soviet countries: A systematic review. <i>PLoS ONE</i> , 2017, 12, e0174373.	2.5	25
127	Initiation, scale-up and outcomes of the Cambodian National MDR-TB programme 2006â€“2016: hospital and community-based treatment through an NGOâ€“NTP partnership. <i>BMJ Open Respiratory Research</i> , 2018, 5, e000256.	3.0	8
128	Successful expansion of communityâ€“based drugâ€“resistant TB care in rural Eswatini â€“ a retrospective cohort study. <i>Tropical Medicine and International Health</i> , 2019, 24, 1243-1258.	2.3	3
129	Treatment outcomes of multi drug resistant and rifampicin resistant Tuberculosis in Zimbabwe: A cohort analysis of patients initiated on treatment during 2010 to 2015. <i>PLoS ONE</i> , 2020, 15, e0230848.	2.5	9
130	Experiences and needs of patients with MDR/XDR-TB: a qualitative study among Saharia tribe in Madhya Pradesh, Central India. <i>BMJ Open</i> , 2021, 11, e044698.	1.9	8
132	Randomized Trials to Optimize Treatment of Multidrug-Resistant Tuberculosis. <i>PLoS Medicine</i> , 2007, 4, e292.	8.4	63
133	Scaling Up Programmatic Management of Drug-Resistant Tuberculosis: A Prioritized Research Agenda. <i>PLoS Medicine</i> , 2008, 5, e150.	8.4	42



#	ARTICLE	IF	CITATIONS
134	Multidrug-Resistant Tuberculosis Treatment Outcomes in Karakalpakstan, Uzbekistan: Treatment Complexity and XDR-TB among Treatment Failures. PLoS ONE, 2007, 2, e1126.	2.5	84
135	Clinical and Microbiological Features of HIV-Associated Tuberculous Meningitis in Vietnamese Adults. PLoS ONE, 2008, 3, e1772.	2.5	82
136	Ambulatory-Based Standardized Therapy for Multi-Drug Resistant Tuberculosis: Experience from Nepal, 2005–2006. PLoS ONE, 2009, 4, e8313.	2.5	35
137	Trends in multidrug-resistant tuberculosis. Journal of Venomous Animals and Toxins Including Tropical Diseases, 2008, 14, 203-223.	1.4	4
138	Sociocultural Epidemiology and Medical Anthropology of Multi-Drug Resistant Tuberculosis (MDR) Treatment Regimens: A Cross-Sectional Study of Patients in a High Prevalence Area. SSRN Electronic Journal, 0, , .	0.4	1
139	Decentralized care for multidrug-resistant tuberculosis: a systematic review and meta-analysis. Bulletin of the World Health Organization, 2017, 95, 584-593.	3.3	53
140	Worldwide Emergence of Extensively Drug-resistant Tuberculosis. Emerging Infectious Diseases, 2007, 13, 380-387.	4.3	477
141	First-Line Drug Resistance Patterns of <i>Mycobacterium tuberculosis</i> Complex Isolates from Re-Treatment Patients from Sudan. Journal of Tuberculosis Research, 2016, 04, 98-104.	0.2	5
142	The potential role of garlic ( <i>Allium sativum</i> ) against the multi-drug resistant tuberculosis pandemic: a review. Annali Dell'Istituto Superiore Di Sanita, 2011, 47, 465-73.	0.4	23
143	High rates of culture conversion and low loss to follow-up in MDR-TB patients managed at Regional Referral Hospitals in Uganda. BMC Infectious Diseases, 2021, 21, 1060.	2.9	3
144	Multidrug Resistant TB, TB Control, and Millennium Development Goals in Asia. , 2008, , 209-231.		0
146	Antituberculosis agents. , 2010, , 1415-1430.		0
147	Control of Tuberculosis in High-Prevalence Countries. , 2014, , 377-404.		0
149	Field-testing a pedagogical evaluation system for assessing skills of patients with drug-resistant tuberculosis. Education Therapeutique Du Patient, 2015, 7, 10101.	1.0	0
150	Strengthening the response to drug-resistant TB in Pakistan: a practice theory-informed approach. Public Health Action, 2020, 10, 147-156.	1.2	4
151	Adherence to the MDR-TB intensive phase treatment protocol amongst individuals followed up at central and peripheral health care facilities in Uganda - a descriptive study. African Health Sciences, 2020, 20, 625-632.	0.7	3
152	Unsuccessful treatment outcome and associated risk factors. A prospective study of DR-TB patients from a high burden country, Pakistan. PLoS ONE, 2023, 18, e0287966.	2.5	0